Cargando…
Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease
Intestinal fibrosis is one of the most threatening complications of Crohn’s disease. It occurs in more than a third of patients with this condition, is associated with increased morbidity and mortality, and surgery often represents the only available therapeutic option. The mechanisms underlying int...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834168/ https://www.ncbi.nlm.nih.gov/pubmed/35159238 http://dx.doi.org/10.3390/cells11030429 |
_version_ | 1784649118895833088 |
---|---|
author | Santacroce, Giovanni Lenti, Marco Vincenzo Di Sabatino, Antonio |
author_facet | Santacroce, Giovanni Lenti, Marco Vincenzo Di Sabatino, Antonio |
author_sort | Santacroce, Giovanni |
collection | PubMed |
description | Intestinal fibrosis is one of the most threatening complications of Crohn’s disease. It occurs in more than a third of patients with this condition, is associated with increased morbidity and mortality, and surgery often represents the only available therapeutic option. The mechanisms underlying intestinal fibrosis are partly known. Studies conducted so far have shown a relevant pathogenetic role played by mesenchymal cells (especially myofibroblasts), cytokines (e.g., transforming growth factor-β), growth factors, microRNAs, intestinal microbiome, matrix stiffness, and mesenteric adipocytes. Further studies are still necessary to elucidate all the mechanisms involved in intestinal fibrosis, so that targeted therapies can be developed. Although several pre-clinical studies have been conducted so far, no anti-fibrotic therapy is yet available to prevent or reverse intestinal fibrosis. The aim of this review is to provide an overview of the main therapeutic targets currently identified and the most promising anti-fibrotic therapies, which may be available in the near future. |
format | Online Article Text |
id | pubmed-8834168 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88341682022-02-12 Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease Santacroce, Giovanni Lenti, Marco Vincenzo Di Sabatino, Antonio Cells Review Intestinal fibrosis is one of the most threatening complications of Crohn’s disease. It occurs in more than a third of patients with this condition, is associated with increased morbidity and mortality, and surgery often represents the only available therapeutic option. The mechanisms underlying intestinal fibrosis are partly known. Studies conducted so far have shown a relevant pathogenetic role played by mesenchymal cells (especially myofibroblasts), cytokines (e.g., transforming growth factor-β), growth factors, microRNAs, intestinal microbiome, matrix stiffness, and mesenteric adipocytes. Further studies are still necessary to elucidate all the mechanisms involved in intestinal fibrosis, so that targeted therapies can be developed. Although several pre-clinical studies have been conducted so far, no anti-fibrotic therapy is yet available to prevent or reverse intestinal fibrosis. The aim of this review is to provide an overview of the main therapeutic targets currently identified and the most promising anti-fibrotic therapies, which may be available in the near future. MDPI 2022-01-26 /pmc/articles/PMC8834168/ /pubmed/35159238 http://dx.doi.org/10.3390/cells11030429 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Santacroce, Giovanni Lenti, Marco Vincenzo Di Sabatino, Antonio Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease |
title | Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease |
title_full | Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease |
title_fullStr | Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease |
title_full_unstemmed | Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease |
title_short | Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease |
title_sort | therapeutic targeting of intestinal fibrosis in crohn’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834168/ https://www.ncbi.nlm.nih.gov/pubmed/35159238 http://dx.doi.org/10.3390/cells11030429 |
work_keys_str_mv | AT santacrocegiovanni therapeutictargetingofintestinalfibrosisincrohnsdisease AT lentimarcovincenzo therapeutictargetingofintestinalfibrosisincrohnsdisease AT disabatinoantonio therapeutictargetingofintestinalfibrosisincrohnsdisease |